Naproxen for the Prevention of HO After Complex Elbow Trauma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE4

Study Classification

INTERVENTIONAL

Study Start Date

2007-10-31

Study Completion Date

2010-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Complex elbow fractures can lead to formation of new bone (called Heterotopic ossification). This new bone is unwanted and it can restrict motion. This research study is being done to learn more about the effect of the drug naproxen, on unwanted formation of new bone around the elbow as it heals after a fracture. Naproxen belongs to a class of drugs called NSAIDs which stands for non-steroidal anti-inflammatory drugs.

Several research studies suggest that NSAIDs such as Naproxen can prevent the unwanted formation of new bone around the hip. The effect of NSAIDS on the formation of bone around the elbow has not been studied as well as it has been studied for their effect on the hip.

The drug, Naproxen is approved by the US food and drug administration (FDA) for sale but ot specifically for the treatment of heterotopic ossification.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Tranexamic Acid Prophylaxis for Heterotopic Ossification in Elbow Fracture-Dislocation Surgery

NCT06088407

Elbow Dislocation Heterotopic Ossification

COMPLETED NA

Fracture and Neurological Injury

NCT05075382

Elbow Fracture Neurologic Deficits

WITHDRAWN

Osteogenon in Orthopedics and Traumatology

NCT07210281

Patients With Fractures

RECRUITING PHASE4

Variation in Humeral Head Bone Marrow Characteristics with Rotator Cuff Repair Healing

NCT05106088

Rotator Cuff Tears Rotator Cuff Repairs

ACTIVE_NOT_RECRUITING

Proximal Humerus Fracture Dislocation Direction and Avascular Necrosis

NCT05735561

Proximal Humeral Fracture Dislocation Dislocation Shoulder +2 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heterotopic Ossification

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Will receive 500 mg Naproxen twice a day for two weeks

Group Type EXPERIMENTAL

Naproxen

Intervention Type DRUG

500 mg Naproxen twice a day for two weeks

2

Will not receive naproxen

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Naproxen

500 mg Naproxen twice a day for two weeks

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subjects aged 18 years or greater
2. Operative treatment of one of the following injuries

* An elbow dislocation with or without associated fractures
* An olecranon fracture-dislocation, but not simple olecranon fractures
* A distal humerus fracture

Exclusion Criteria

1. An existing diagnosis of one of the following conditions

* Injury to the central nervous system, thorax, or abdomen precluding the immediate use of non-steroidal anti-inflammatory medications
* Fracture of any long bone since non-steroidal anti-inflammatory medications may increase the risk of nonunion
* History of gastritis, peptic ulcer disease, or upper gastrointestinal bleeding
* Impaired renal function (creatinine \> 2.0), hypovolemia, heart failure, high blood pressure ( \> 160/90), fluid retention, asthma, liver dysfunction (bilirubin \> 2.0), or a coagulation disorder
* Allergy to non-steroidal anti-inflammatory medications
* Asthma, nasal polyps, urticaria, and hypotension associated with the use of NSAIDs
* Considerable dehydration
2. Pregnant or breast-feeding women
3. Concomitant use of one of the following drugs:

* Aspirin
* Other naproxen products (ec-naprosyn, anaprox, anaprox ds, naprosyn suspension, aleve)
* Methotrexate
* Diuretics (thiazides / furosemide)
* ACE-inhibitors (captopril, enalapril, ramipril etc.)
* Beta-blockers (propanolol etc.)
* Probenecid (for gout or hyperuricemia)
* H2-blockers, sucralfate and intensive antacid therapy
* Lithium
* Anticoagulants / Warfarin (coumadin, waran, jantoven etc.)
* Sulfonamides
* Anticonvulsant medication (peganone, mesantoin, cerebyx, dilantin, etc.)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes